AzTrials
AzTrials

Gut Microbiota, PICSNCT04455061

Intestinal Flora Research Plan for Critically Ill Patients

An observational study of Gut Microbiota, PICS, run by Chinese Medical Association at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

More and more critically ill patients have improved early survival, they have been suffering from organ damage and inflammation for a long time, which is called chronic critical illness (CCI). Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Gut Microbiota, PICS
How many people
300 participants
Where
1 siteChina
Study dates
1 Jan 2020to 30 Dec 2022
How long will I take part?
1 Month
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: In order to further understand and grasp the relationship between the intestinal microflora in critically ill patients, the relationship with the progression of critical illness, the outcome of the disease and the final prognosis, it is now planned to analyze the dynamic intestinal microflora changes in critically ill patients through 16SrRNA technology.

Who may be able to join

  • Age 18-75 years old
  • Expect to stay in the ICU for more than 7 days after enrollment;
  • Initial disease, not receiving ICU special treatment;

Who cannot join

  • Does not meet the inclusion criteria;
  • Complicated with perianal infection, intestinal fistula, short bowel syndrome, chronic severe gastrointestinal disease;
  • Patients with malignant tumors undergoing chemotherapy and radiotherapy;
  • Taking probiotic preparations within the past 3 months, etc. Intestinal flora regulator.

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • The Affliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, Jiangsu, 210008

    Wenkui Yu, 02568182222 ext. 60506, yudrnj@163.com

    Recruiting

Other trials in China

About this study

Official title: Intestinal Flora Research Plan for Critically Ill Patients-- Study on the Relationship Between Microbial Disorder and Disease Severity, Prognosis

More and more critically ill patients have improved early survival, they have been suffering from organ damage and inflammation for a long time, which is called chronic critical illness (CCI). Among CCI, persistent inflammatory response-immunosuppression-catabolic syndrome (PICS) is a special type of chronic severe disease, and immune paralysis is its main feature. The clinical manifestations are repeated nosocomial infections, malnutrition, muscle loss, and difficulty in wound healing and require long-term emergency medical support, which ultimately leads to patients Repeated nosocomial infections, prolonged hospitalization, and increased mortality.

The gut provides the microbiome with habitat and the nutrients it needs, down-regulates the immune response to form immune tolerance, and promotes its colonization in the intestine.Under physiological conditions, the mutually beneficial symbiosis of the intestine and microorganisms promotes the body's homeostasis. The composition and biodiversity of the microbial community are highly susceptible to various factors, including diet, environment, drugs, infections, inflammation, etc. Especially for acute stress, severe stress, the use of broad-spectrum antibiotics, vasoconstrictors and opioids, intestinal ischemia/reperfusion injury, epithelial cell apoptosis, barrier integrity destruction, gastrointestinal Changes in the motility of the tract, lack of nutrients in the intestinal cavity, etc. All those can lead to rapid changes in the intestinal flora, and this change can last for a long time; manifested by the loss of the richness and diversity of the intestinal microflora (especially the symbiotic flora), The ratio of Bacteroidetes/thickwalled bacteria is severely unbalanced, and a single flora (often a potential pathogen) overgrows, that is, bacterial flora imbalance or microecological disturbance.

At present, for critically ill patients, there are few relevant studies, and currently limited to small-scale, single cross-sectional studies. These studies have uncovered the changes and impacts of intestinal microbiota in critically ill patients in ICU, but they are still in the stage of touching the image of blind people. The relevant mechanisms and dynamic changes and their significance are unclear, requiring large-scale, dynamic, continuous and comprehensive In order to accurately grasp the role of intestinal flora in the development and prognosis of the disease, we hope to accurately control the intestinal flora and achieve effective treatment.

Read the detailed description

With the improvement and development of medical technology and concepts, the types, progression, and outcomes of critically ill patients have changed dramatically. More and more critically ill patients can successfully escape from the early critical state, and the outbreak of multiple organ failure has been alleviated. However, due to the residual organ dysfunction, the number of cases staying in the intensive care department for a long time is increasing. Both severe trauma and sepsis undergo similar transformations. Although these patients have improved early survival, they have been suffering from organ damage and inflammation for a long time, which is called chronic critical illness (CCI). The definition of CCI includes the number of days of ICU hospitalization greater than or equal to 14 days, evidence of persistent organ dysfunction, and can be measured using components of the 14-day Sequential Organ Failure Assessment (SOFA) score. Even nearly 40% of sepsis patients will develop CCI. These critical survivors continue to recover and support treatment even after being discharged from the hospital, often failing to recover and eventually die. Among them, persistent inflammatory response-immunosuppression-catabolic syndrome (PICS) is a special type of chronic severe disease, and immune paralysis is its main feature. These patients also face several challenges such as persistent inflammatory response, acquired immunosuppression, and high catabolism. The clinical manifestations are repeated nosocomial infections, malnutrition, muscle loss, and difficulty in wound healing and require long-term emergency medical support, which ultimately leads to patients Repeated nosocomial infections, prolonged hospitalization, and increased mortality.

Due to the decline in organ function reserve of elderly patients, chronic diseases of basic heart, lung, kidney and other systems are often combined. After suffering trauma and severe infection, organ function disorders or failures are prone to occur and stay in the ICU ward. With the advent of an aging population, such patients are increasing year by year. It is a heavy burden on society and a huge challenge for the future development and progress of ICU.

The gut flora is involved in a wide range of functions, food digestion, hormone production, and the development and maturation of the immune system. After more than a billion years of co-evolution, a stable symbiotic relationship has been formed between mammals including humans and the gut microbiota. The gut provides the microbiome with habitat and the nutrients it needs, down-regulates the immune response to form immune tolerance, and promotes its colonization in the intestine; accordingly, the gut symbiotic microbiota promotes the health of the body in various ways to form symbiosis Mode: (1) Inhibiting the colonization of pathogenic bacteria by competing for niche and nutrients, producing virulence factors, and secreting bacteriocins, preventing their overgrowth, and protecting the body from pathogen infection, called colonization resistance; (2 ) Promote the proliferation of epithelial cells, secrete antimicrobial peptides and mucus to maintain the integrity of the intestinal barrier; (3) Indirectly regulate the differentiation of innate and adaptive immune cells located in the intestinal epithelial barrier and the whole body, promote the development and maturation of the immune system, and strengthen immune cells Function; (4) Induce extravascular tissue factor-protease activated receptor 1 (TF-PAR1) signal transduction, promote small intestine angiogenesis; (5) participate in hormone signal transduction, regulate intestinal endocrine function; (6) participate in intestinal origin Serotonin (5-HT) metabolism and intestinal neuro-immune cooperation, regulate gastrointestinal motility; (7) produce short-chain fatty acids (SCFAs) by fermenting dietary fiber, improve glucose homeostasis and insulin sensitivity, participate in anti-inflammatory, Promote intestinal motility; (8) Synthesize essential vitamins and neurotransmitters and metabolize bile salts; (9) Participate in body drug metabolism and poison removal. This shows that under physiological conditions, the mutually beneficial symbiosis of the intestine and microorganisms promotes the body's homeostasis. The composition and biodiversity of the microbial community are highly susceptible to various factors, including diet, environment, drugs, infections, inflammation, etc. Especially for acute stress, severe stress, the use of broad-spectrum antibiotics, vasoconstrictors and opioids, intestinal ischemia/reperfusion injury, epithelial cell apoptosis, barrier integrity destruction, gastrointestinal Changes in the motility of the tract, lack of nutrients in the intestinal cavity, etc. lead to rapid changes in the intestinal flora, and this change can last for a long time; manifested by the loss of the richness and diversity of the intestinal microflora (especially the symbiotic flora), The ratio of Bacteroidetes/thickwalled bacteria is severely unbalanced, and a single flora (often a potential pathogen) overgrows, that is, bacterial flora imbalance or microecological disturbance.

The local immune inflammatory storm in the intestine is an important cause of the imbalance of the systemic immune inflammatory response, and the hypothalamic metabolism center is an important target for regulating the body's continuous catabolism. In PICS, immunosuppression, inflammation, and catabolism are mutually causal, forming a vicious circle. So what is the reason for severe patients with different primary diseases to have the same PICS after the acute phase? Are there common pathological changes induced by PICS in severe patients? If further studies can be made to clarify the initiating factors of PICS and the path of occurrence and development of PICS, it is undoubtedly a new breakthrough in the treatment of PICS and the "fundamental" way to reduce the mortality of PICS patients. Combining our previous research results, applicants speculate as follows:

  1. The intestinal tract is the "promoting point" for the occurrence of PICS in severely ill patients, and it is also the "central organ" that promotes the development of the disease; 2. The disturbance of the micro-ecology of the intestinal tract is an important reason for causing PICS in the body (and may even be the decisive factor) ; 3. Correction of intestinal microecological disturbances can effectively block the path of PICS development.

For the above ideas, specific explanations are as follows:

  1. The intestine may be the "promoting point" for PICS in critically ill patients, and it is also the "central organ" that promotes the development of the disease. The reasons are as follows:
  • Our previous studies showed that acute gastrointestinal dysfunction is common in severe patients. Whether it is local simple abdominal exposure injury or systemic ischemia-reperfusion injury, it can cause acute gastrointestinal dysfunction; ②The intestine is not only the main organ of digestion and absorption, but also the body's largest immune organ (adult). When the intestine is acutely damaged, the intestine can affect the nutritional metabolism center of the hypothalamus through Grelin and other hormones, leading to refractory catabolism and exogenous nutrition. At the same time, the local inflammatory reaction of the intestinal tract can also cause an imbalance of the body's immune inflammatory response. In addition, changes in central metabolism in critically ill patients are related to hypothalamic inflammation (indicating that the intestine is "capable" to become the central organ that promotes the occurrence and development of PICS).

Intestinal microecological disturbance is an important cause of PICS Under normal physiological conditions, the intestine has powerful barrier functions, such as physical barrier, chemical barrier, immune barrier, and biological barrier. Especially its biological barrier function plays an important role in the body's metabolism and immunity. There is a stable symbiotic relationship between the human body and the intestinal microbiota. The intestine provides the microbiome with habitat and the nutrients it needs to downregulate the immune response to form immune tolerance and promote its colonization in the intestine; accordingly, the physiological state Next, the gut symbiotic microbiota also maintains the body's health in various ways [2]. The intestine and microorganisms are symbiotic and promote the body's homeostasis. However, the composition and biodiversity of the microbial community are highly susceptible to various factors, including diet, environment, drugs, infections, inflammation, etc.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 28-day mortality

    The patient's 28-day mortality rate is the survival rate from the onset to the disease at 28 days, compared with the total number of illnesses, to assess the severity of the disease

    Measured: up to 28 days after hospitalized.

Secondary outcomes (1)
  1. the duration of intensive care unit

    time for patients treatment in intensive care unit is patient total treated days in intensive care unit.

    Measured: Up to 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jul 2020
  2. Study start1 Jan 2020
  3. Primary completion30 Dec 2022 (estimated)
  4. Study completion30 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
300 participants (estimated)
Target duration
1 Month
IDs, dates and publications
ClinicalTrials.gov ID
NCT04455061
Sponsor's protocol ID
2020-01-01
Status last verified
Jan 2020
First submitted
29 Jun 2020
Last updated
2 Jul 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Chen X, Li H, Huang S, Chen M, Huang S, Zhu Z, You Y, Xu G, Wang Y, Wang R, Yu W. ROLE OF CHANGES IN LIPOPROTEINS, LIPIDOMES, AND GUT MICROBIOTA IN THE PATHOGENESIS OF PERSISTENT INFLAMMATION, IMMUNOSUPPRESSION, AND CATABOLISM SYNDROME: A PROSPECTIVE COHORT STUDY. Shock. 2025 Sep 1;64(3):322-331. doi: 10.1097/SHK.0000000000002634.

    PubMed 40844181

Questions about this trial

What is this clinical trial studying?

An observational study of Gut Microbiota, PICS, run by Chinese Medical Association at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 2 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

28-day mortality (time frame: up to 28 days after hospitalized.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04455061, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in